Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 2/2012

01.06.2012 | short review

Recent advances and future challenges in the treatment of upper gastrointestinal malignancies

verfasst von: Dieter Koeberle, MD, Anna Dorothea Wagner, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

This update includes articles on upper GI-cancers published in 2011 and in early 2012, which we consider particularly interesting for medical oncologists. In addition, abstracts from the 2011 ASCO meeting are also considered We reviewed the important literature in the field of GI-oncology and selected articles, which addressed key topics related to the treatment of esophageal and gastric cancer, and of cancers of the pancreas, the ampulla of Vater and the biliary tract, respectively. As the format of a short review is limited, we have focused on articles which are considered relevant for routine care.
Literatur
1.
Zurück zum Zitat Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.CrossRefPubMed Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.CrossRefPubMed
2.
Zurück zum Zitat Lee J, Park SH, Chang H-M, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicenter, open-label, randomized, phase 3 study. Lancet Oncol. 2011 Dec 20; [Epub ahead of print]. Lee J, Park SH, Chang H-M, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicenter, open-label, randomized, phase 3 study. Lancet Oncol. 2011 Dec 20; [Epub ahead of print].
3.
Zurück zum Zitat Bekaii-Saab T, Phelps MA, Li X, et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011;29(17):2357–63CrossRefPubMed Bekaii-Saab T, Phelps MA, Li X, et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011;29(17):2357–63CrossRefPubMed
4.
Zurück zum Zitat Yi JH, Thongpraesert S, Lee J, et al. A phase II study of sunitib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study. Eur J Cancer. 2011 Dec 14; [Epub ahead of print]. Yi JH, Thongpraesert S, Lee J, et al. A phase II study of sunitib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study. Eur J Cancer. 2011 Dec 14; [Epub ahead of print].
5.
Zurück zum Zitat Neoptolomos JP MM, Cox TF, Valle JW, et al. Ampullary cancer espac-3 (v2) trial: a multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of Vater. J Clin Oncol. 2011;29:Abst.LBA4006. Neoptolomos JP MM, Cox TF, Valle JW, et al. Ampullary cancer espac-3 (v2) trial: a multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of Vater. J Clin Oncol. 2011;29:Abst.LBA4006.
6.
Zurück zum Zitat Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25CrossRefPubMed Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25CrossRefPubMed
7.
Zurück zum Zitat Assaf E, Verlinde-Carvalho M, Delbaldo C, et al. 5-Fluorouracil/leucovorin combined with irinitecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology. 2011;80(5–6);301–6.CrossRefPubMed Assaf E, Verlinde-Carvalho M, Delbaldo C, et al. 5-Fluorouracil/leucovorin combined with irinitecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology. 2011;80(5–6);301–6.CrossRefPubMed
8.
Zurück zum Zitat Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nob-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29(34):4548–54.CrossRef Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nob-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29(34):4548–54.CrossRef
9.
Zurück zum Zitat Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefPubMed Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefPubMed
10.
Zurück zum Zitat Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–49.CrossRefPubMed Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–49.CrossRefPubMed
11.
Zurück zum Zitat Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.CrossRefPubMed Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.CrossRefPubMed
12.
Zurück zum Zitat Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28(35):5210–8.CrossRefPubMed Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28(35):5210–8.CrossRefPubMed
13.
Zurück zum Zitat Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.CrossRefPubMed Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.CrossRefPubMed
14.
Zurück zum Zitat Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.CrossRefPubMed Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.CrossRefPubMed
15.
Zurück zum Zitat Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303(17):1729–37.CrossRefPubMed Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303(17):1729–37.CrossRefPubMed
16.
Zurück zum Zitat Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268–73.CrossRefPubMed Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268–73.CrossRefPubMed
17.
Zurück zum Zitat Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687–97. Erratum in: Lancet. 2010 Oct 16;376(9749):1302. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687–97. Erratum in: Lancet. 2010 Oct 16;376(9749):1302.
18.
Zurück zum Zitat Wagner AD, Arnold D, Grothey AA, et al. Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev. 2009;(3):CD005392. Wagner AD, Arnold D, Grothey AA, et al. Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev. 2009;(3):CD005392.
19.
Zurück zum Zitat Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968–76.CrossRefPubMed Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968–76.CrossRefPubMed
20.
Zurück zum Zitat Park SH, Lim DH, Lee S, et al. A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with best supportive care alone for pretreated advanced gastric cancer (AGC). J Clin Oncol. 2011;29:Abst.4004.CrossRef Park SH, Lim DH, Lee S, et al. A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with best supportive care alone for pretreated advanced gastric cancer (AGC). J Clin Oncol. 2011;29:Abst.4004.CrossRef
21.
Zurück zum Zitat Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second- line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47(15):2306–14.CrossRefPubMed Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second- line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47(15):2306–14.CrossRefPubMed
22.
Zurück zum Zitat Moehler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D, et al. German S3-guideline “Diagnosis and treatment of esophagogastric cancer”. Z Gastroenterol. 2011;49(4):461–531.CrossRefPubMed Moehler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D, et al. German S3-guideline “Diagnosis and treatment of esophagogastric cancer”. Z Gastroenterol. 2011;49(4):461–531.CrossRefPubMed
Metadaten
Titel
Recent advances and future challenges in the treatment of upper gastrointestinal malignancies
verfasst von
Dieter Koeberle, MD
Anna Dorothea Wagner, MD
Publikationsdatum
01.06.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0001-8

Weitere Artikel der Ausgabe 2/2012

memo - Magazine of European Medical Oncology 2/2012 Zur Ausgabe